
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### **Step-by-Step Analysis:**<br><br>#### **1. List the Key Functional Markers:**<br>The top markers are dominated by **immunoglobulin (Ig) genes** and **B-cell/plasma cell-related genes**:<br>- **IGLL5** (Immunoglobulin Lambda Like Polypeptide 5): Essential for B-cell development and pre-B-cell receptor formation.<br>- **JCHAIN** (Joining Chain of Multimeric IgA and IgM): Critical for polymeric Ig secretion (IgA/IgM).<br>- **IGLC3, IGLC2, IGLV6-57, IGKV4-1, IGKV1-5, IGHG1, IGHM, IGHA1, IGHA2**: Immunoglobulin light/heavy chains (IgA, IgG, IgM).<br>- **TNFRSF17 (BCMA)**: B-cell maturation antigen, highly expressed in plasma cells.<br>- **MZB1**: Marginal zone B and plasma cell-specific chaperone for Ig secretion.<br>- **DERL3**: ER-associated degradation (ERAD) component, highly expressed in antibody-secreting cells.<br>- **FCRL5 (Fc Receptor-Like 5)**: Expressed in memory B cells and plasma cells.<br>- **CCR10**: Chemokine receptor associated with mucosal IgA plasma cells.<br><br>**Functional Interpretation:**  <br>This cluster is strongly enriched for **immunoglobulin production**, **antibody secretion**, and **B-cell/plasma cell function**.<br><br>---<br><br>#### **2. List the Key Cell Type Markers:**<br>The markers strongly suggest **B-cell lineage**, specifically **plasma cells**:<br>- **Plasma Cell Markers**:  <br>  - **IGLL5, JCHAIN, MZB1, TNFRSF17, DERL3, IGLC3, IGLC2, IGHA1, IGHA2, IGHG1, IGHM**  <br>  - **FCRL5, CCR10** (mucosal homing)  <br>- **B-Cell Markers (but less dominant)**:  <br>  - **IGKC, IGKV4-1, IGKV1-5** (also present in plasma cells)  <br><br>**Key Observations:**  <br>- The dominance of **IgA/IgG heavy chains (IGHA1, IGHA2, IGHG1)** and **JCHAIN** suggests **antibody-secreting plasma cells**.<br>- **CCR10** is a strong indicator of **mucosa-associated plasma cells** (e.g., gut-resident IgA plasma cells).<br>- **TNFRSF17 (BCMA)** is a canonical plasma cell marker.<br><br>---<br><br>#### **3. Cross-reference Known Databases:**<br>- **Human Cell Atlas (HCA)**:  <br>  - Plasma cells in the gut express **IGHA1, IGHA2, JCHAIN, MZB1, DERL3, CCR10**.<br>  - **CCR10+ plasma cells** are enriched in mucosal tissues (intestine).<br>- **ImmGen/HPCA**:  <br>  - **IGLL5, JCHAIN, MZB1, TNFRSF17** are top plasma cell markers.<br>  - **FCRL5** is associated with long-lived plasma cells.<br>- **Literature (PMID: 31048361, PMID: 31231008)**:  <br>  - Gut plasma cells are **IgA-dominated** and express **CCR10** for mucosal retention.<br><br>---<br><br>#### **4. Determine the Most Probable General Cell Type:**<br>**Plasma Cell** (terminally differentiated B-cell subset specialized for antibody secretion).<br><br>---<br><br>#### **5. Identify the Top 3 Most Probable Sub Cell Types:**<br>Based on **Ig isotype dominance** and **tissue-specific markers**, the most likely subtypes are:<br>1. **IgA+ Plasma Cell (Mucosal, CCR10+)**  <br>   - **Key markers**: IGHA1, IGHA2, JCHAIN, CCR10, DERL3  <br>   - Most probable due to **gut tissue origin** and **IgA dominance**.<br>2. **IgG+ Plasma Cell**  <br>   - **Key markers**: IGHG1, IGHG3, TNFRSF17  <br>   - Less likely in gut but present in chronic inflammation.<br>3. **Long-lived Plasma Cell (FCRL5+)**  <br>   - **Key markers**: FCRL5, TNFRSF17, MZB1  <br>   - Possible but less dominant than IgA+.<br><br>**Final Subtype:**  <br>**IgA+ CCR10+ Mucosal Plasma Cell** (most consistent with gut tissue).<br><br>---<br><br>### **6. Concise Summary of Analysis:**<br>- **Dominant markers**: IGLL5, JCHAIN, IGHA1, IGHA2, CCR10, MZB1, TNFRSF17.  <br>- **Functional role**: Antibody (IgA) secretion, mucosal immunity.  <br>- **General cell type**: Plasma cell.  <br>- **Most probable subtype**: **IgA+ CCR10+ mucosal plasma cell** (gut-resident).  <br>- **Supporting evidence**:  <br>  - High IgA heavy/light chain expression.  <br>  - CCR10 (mucosal homing).  <br>  - JCHAIN (polymeric IgA/M secretion).  <br>  - TNFRSF17 (BCMA, plasma cell identity).  <br><br>**FINAL ANNOTATION COMPLETED.**  <br><br>---<br><br>### **Validation Notes:**  <br>If additional data (e.g., pseudotime, differential expression vs. other B-cells) is available, further refinement (e.g., cycling vs. quiescent plasma cells) could be done. However, current markers strongly support **mucosal IgA plasma cells**.  <br><br>Would you like additional refinement (e.g., disease-associated plasma cells)?
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED  <br><br>### **Feedback:**  <br>The annotation **"IgA+ CCR10+ Mucosal Plasma Cell"** is strongly supported by the provided marker list and biological context.  <br><br>#### **Key Validations:**  <br>1. **Marker Consistency:**  <br>   - **Plasma cell markers (IGLL5, JCHAIN, MZB1, TNFRSF17, DERL3, IGHA1, IGHA2, IGHG1, IGHM)** are all present in the ranked list.  <br>   - **Mucosal homing marker (CCR10)** is confirmed.  <br>   - **IgA dominance (IGHA1, IGHA2, JCHAIN)** aligns with gut-resident plasma cells.  <br><br>2. **No Evidence of Mixed Populations:**  <br>   - No conflicting markers (e.g., naive B-cell or cycling plasma cell genes like **MKI67**) are dominant.  <br>   - The absence of **CD19/CD20** (B-cell markers) further supports a pure plasma cell identity.  <br><br>3. **Biological Plausibility:**  <br>   - The combination of **IgA heavy chains + CCR10 + JCHAIN** is characteristic of mucosal plasma cells (e.g., gut, respiratory tract).  <br>   - **TNFRSF17 (BCMA)** and **FCRL5** reinforce long-lived/terminally differentiated plasma cells.  <br><br>#### **Minor Considerations (Optional Refinement):**  <br>- If spatial transcriptomics or protein-level data (e.g., IgA secretion) is available, confirm tissue localization.  <br>- **FCRL5** could hint at a long-lived subset, but this doesn‚Äôt conflict with the primary annotation.  <br><br>**Conclusion:** The annotation is biologically sound and marker-validated. Proceed with confidence.  <br><br>---  <br>**Would you like to explore disease-associated signatures (e.g., multiple myeloma markers) for further refinement?**
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Plasma Cell</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>IgA+ Plasma Cell (Mucosal, CCR10+)</li><li>IgG+ Plasma Cell</li><li>Long-lived Plasma Cell (FCRL5+)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">98</div>
                        <div class="scoring-content">
                            The annotation results provided are highly accurate and well-supported by the marker genes listed. Here‚Äôs a detailed evaluation:<br><br>### **Strengths:**<br>1. **Correctness of Annotations:**<br>   - The annotation as **"IgA+ CCR10+ Mucosal Plasma Cell"** is scientifically sound. The markers strongly support this conclusion:<br>     - **IGHA1, IGHA2, JCHAIN**: Dominant IgA-related genes, consistent with mucosal plasma cells.<br>     - **CCR10**: Mucosal homing receptor, specific to gut-resident plasma cells.<br>     - **TNFRSF17 (BCMA), MZB1, DERL3**: Canonical plasma cell markers.<br>   - The analysis cross-references databases (Human Cell Atlas, ImmGen) and literature, reinforcing the validity.<br><br>2. **Balanced Consideration of Markers:**<br>   - The analysis does not overemphasize a single marker but integrates multiple lines of evidence:<br>     - Immunoglobulin genes (IGHA1, IGHA2, IGHG1, IGLC3, etc.) for antibody secretion.<br>     - Plasma cell identity markers (JCHAIN, MZB1, TNFRSF17).<br>     - Tissue-specific markers (CCR10 for mucosal homing).<br>   - The rank of markers is considered (e.g., **IGLL5, JCHAIN** appear early, supporting their importance).<br><br>3. **Comprehensive View of Cell Types:**<br>   - The annotation captures the dominant population (IgA+ plasma cells) while acknowledging minor subsets (IgG+ and FCRL5+ plasma cells).<br>   - No evidence of mixed populations (e.g., absence of naive B-cell markers like CD19/CD20).<br><br>4. **Biological Plausibility:**<br>   - The combination of IgA dominance, CCR10, and gut origin aligns perfectly with known biology of mucosal immunity.<br><br>### **Weaknesses (Minor):**<br>1. **Optional Refinements:**<br>   - The analysis mentions **FCRL5+ long-lived plasma cells** but does not explore whether this subset is functionally distinct in the dataset. This could be clarified with additional data (e.g., pseudotime analysis).<br>   - Disease-associated signatures (e.g., multiple myeloma) are flagged for optional refinement but are not critical for this annotation.<br><br>2. **Marker Redundancy:**<br>   - Some immunoglobulin genes (e.g., IGLC3, IGLC2) are highly similar in function. While this doesn‚Äôt hurt the annotation, it could be streamlined.<br><br>### **Justification for Score:**<br>The annotation is nearly flawless, with strong biological and technical validation. The minor weaknesses do not detract from the overall correctness or comprehensiveness.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    